Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHAZOLAMIDE vs ALFENTA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.
FDA: Adjunctive treatment of open-angle glaucoma or secondary glaucoma; preoperative treatment of acute angle-closure glaucoma.,Off-label: Management of idiopathic intracranial hypertension (pseudotumor cerebri); metabolic alkalosis; acute mountain sickness.
Induction and maintenance of anesthesia,Analgesic supplement during surgical procedures,Intravenous use for monitored anesthesia care (MAC)
Oral: 50-100 mg two to three times daily.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
Hepatic metabolism via CYP3A4; metabolites include N-demethylated and S-oxidized products.
Hepatic via CYP3A4 to inactive metabolites; major metabolite is desmethylalfentanil (inactive).
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
~95% bound to plasma proteins (primarily albumin)
Approximately 92% bound, primarily to alpha-1 acid glycoprotein and albumin.
0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid
0.5–1.0 L/kg; reflects moderate tissue distribution; higher Vd in neonates and elderly.
Oral: ~90% (well absorbed); IM: not typically used; IV: 100%
Intravenous: 100%; intramuscular: approximately 90%; intrathecal: approximately 10% (due to systemic absorption following spinal administration).
GFR 10-50 m L/min: Administer every 12 hours; GFR <10 m L/min: Not recommended.
No specific dose adjustment is recommended for renal impairment; however, alfentanil is primarily metabolized in the liver and its pharmacokinetics are not significantly altered in renal failure.
No specific guidelines; use with caution in severe hepatic impairment.
In hepatic impairment (Child-Pugh class A, B, C): Reduce dose by 50% and titrate carefully due to prolonged elimination half-life. Consider lower initial doses and extended dosing intervals.
Oral: 5-10 mg/kg/day divided every 6-8 hours; maximum 30 mg/kg/day.
Children (1-12 years): Induction of anesthesia: 10-20 mcg/kg IV; maintenance: 5-10 mcg/kg IV or infusion 0.5-1 mcg/kg/min. For neonates and infants: Dose individualization required; titrate to effect.
Initiate at low end of dosing range due to age-related renal function decline; monitor electrolytes and renal function.
Elderly patients (>65 years): Reduce initial dose by 30-50% and administer slowly. Due to decreased clearance and increased sensitivity, lower infusion rates (e.g., 0.3-0.5 mcg/kg/min) may be needed.
None.
Risk of respiratory depression, particularly in elderly or debilitated patients. Concomitant use with benzodiazepines or other CNS depressants may cause profound sedation, respiratory depression, coma, and death.
Sulfonamide hypersensitivity reactions; metabolic acidosis; electrolyte disturbances (hypokalemia); drowsiness and confusion; potentiation of acidosis in renal impairment; risk of nephrolithiasis; caution with concomitant use of high-dose aspirin (risk of toxicity).
Respiratory depression; abuse potential; hypotension; bradycardia; muscle rigidity; serotonin syndrome with concurrent serotonergic drugs; adrenal insufficiency; risk of withdrawal with prolonged use.
Hyponatremia or hypokalemia; severe renal or hepatic impairment; adrenal insufficiency; hypersensitivity to sulfonamides or thiazide diuretics; concurrent use with high-dose aspirin.
Hypersensitivity to alfentanil or any component; significant respiratory insufficiency; severe asthma; paralytic ileus; concurrent use of MAOIs (or within 14 days); acute or postoperative pain management in children (except for procedural sedation).
No specific food interactions. Maintain adequate hydration. Avoid excessive intake of sodium bicarbonate or antacids containing bicarbonate.
No known interactions with food. However, grapefruit juice may increase alfentanil serum concentrations due to CYP3A4 inhibition; avoid concurrent consumption.
First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: Risk of fetal acidosis and electrolyte disturbances due to carbonic anhydrase inhibition. Avoid if possible.
Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effects were observed at clinically relevant doses; however, high doses caused embryotoxicity and increased fetal mortality. Trimester-specific risks: First trimester - potential for minor malformations based on limited human data; second trimester - possible risk if used chronically; third trimester - prolonged use may lead to neonatal respiratory depression, withdrawal syndrome, or opioid dependence. Use only if benefits outweigh risks.
Methazolamide is excreted into breast milk; M/P ratio not established. Potential for metabolic acidosis or sulfonamide-related adverse effects in nursing infant. Use only if benefit outweighs risk; consider alternative agents.
Alfentanil is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.3. Estimated infant dose is <1% of maternal weight-adjusted dose, which is considered clinically insignificant. However, due to potential for neonatal opioid effects, caution is advised; monitor infant for drowsiness, respiratory depression, and feeding difficulties. Consider alternative analgesics with established safety profiles, such as acetaminophen or ibuprofen, for lactation.
No pharmacokinetic studies in pregnancy; increased glomerular filtration rate may reduce serum levels. Empirical dose adjustment not recommended; monitor clinical effect and adjust as needed.
Pregnancy can alter pharmacokinetics of alfentanil. Increased plasma volume and distribution may require higher doses to achieve same effect, while decreased plasma protein binding may increase free fraction, potentiating effects. Alpha-1-acid glycoprotein levels change in pregnancy, affecting binding. In third trimester, clearance may be increased by up to 50% due to enhanced hepatic metabolism. Therefore, dose adjustments may be needed: consider starting at low dose and titrating to effect, with close monitoring. For intravenous administration, typical adult doses (5-20 μg/kg) may need adjustments; no standard pregnancy-specific dosing exists. Use the lowest effective dose for the shortest duration. In labor, avoid high doses prior to delivery due to risk of neonatal respiratory depression.
Methazolamide is a carbonic anhydrase inhibitor used for glaucoma. Monitor serum electrolytes, especially potassium, as hypokalemia is common. Contraindicated in patients with hepatic cirrhosis due to risk of hepatic encephalopathy. Avoid in patients with adrenal insufficiency. Adjust dose in renal impairment. Use with caution in patients with pulmonary obstruction or emphysema as it can cause metabolic acidosis.
Alfentanil is a potent, rapid-onset, short-acting opioid analgesic used primarily for induction and maintenance of anesthesia. Due to its high protein binding (90%) and rapid redistribution, it has a shorter duration of action than fentanyl, making it suitable for brief, painful procedures. It undergoes hepatic metabolism via CYP3A4, so concomitant use with CYP3A4 inhibitors like ketoconazole or erythromycin can prolong its effects. Use caution in elderly or hypovolemic patients due to increased risk of hypotension. Naloxone reverses respiratory depression. Alfentanil is 5-10 times less potent than fentanyl.
Take this medication exactly as prescribed, usually twice a day.,You may experience tingling in the fingers or toes, which is common and usually harmless.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of infection, easy bruising, or bleeding.,Do not drive or operate heavy machinery until you know how this medication affects you.,This medication may cause sensitivity to sunlight; use sunscreen and protective clothing.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double dose.
This medication is given only by a healthcare professional in a hospital or surgical setting.,You may feel drowsy, dizzy, or nauseated after receiving this drug.,Report any difficulty breathing or slow heart rate to your healthcare provider immediately.,Avoid alcohol and sedatives for 24 hours after administration, as they can increase side effects.,Do not drive or operate machinery until the effects have fully worn off.
"The combination of Triamterene, a potassium-sparing diuretic that inhibits epithelial sodium channels in the distal nephron, with Methazolamide, a carbonic anhydrase inhibitor that reduces renal bicarbonate reabsorption, can lead to severe hyperkalemia and metabolic acidosis due to additive effects on renal electrolyte handling. Both drugs impair renal potassium secretion, while Methazolamide-induced metabolic acidosis further exacerbates hyperkalemia by shifting potassium extracellularly. This synergistic disruption of acid-base balance and potassium homeostasis significantly increases the risk of life-threatening cardiac arrhythmias and neurological impairment."
"Carteolol, a non-selective beta-blocker, can blunt the compensatory sympathetic response to metabolic acidosis induced by methazolamide, a carbonic anhydrase inhibitor. This can lead to excessive bradycardia, hypotension, and potentially precipitate heart failure. The additive effects on lowering intraocular pressure may also be affected."
"Phentermine, a sympathomimetic amine, may competitively inhibit the renal tubular secretion of methazolamide, a carbonic anhydrase inhibitor primarily eliminated via active tubular secretion. This can lead to reduced clearance and increased systemic exposure of methazolamide, potentially elevating its serum levels and prolonging its therapeutic and adverse effects such as metabolic acidosis, paresthesias, and electrolyte imbalances. Clinical outcomes may include increased risk of methazolamide toxicity, particularly in patients with renal impairment, and enhanced diuretic or ocular hypotensive effects."
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHAZOLAMIDE vs ALFENTA, answered by our medical review team.
METHAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.. ALFENTA is a Opioid Analgesic that works by μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing c AMP production, leading to reduced neuronal excitability and pain transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHAZOLAMIDE and ALFENTA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHAZOLAMIDE is: Oral: 50-100 mg two to three times daily.. The standard adult dose of ALFENTA is: Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METHAZOLAMIDE and ALFENTA. The risk or severity of adverse effects can be increased when Alfentanil is combined with Methazolamide. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METHAZOLAMIDE is classified as Category C. First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: R. ALFENTA is classified as Category C. Alfentanil, a short-acting opioid analgesic, is classified as FDA Pregnancy Category C. No well-controlled studies in pregnant women exist. In animal studies, no teratogenic effect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.